إسرائيل - العبرية - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - קפסולות - ozanimod as hydrochloride 0.46 mg - ozanimod

إسرائيل - العبرية - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - קפסולות - ozanimod as hydrochloride 0.92 mg - ozanimod

إسرائيل - العبرية - Ministry of Health

bristol, myers squibb (israel) limited, israel - luspatercept - אבקה להכנת תמיסה לזריקה - luspatercept 25 mg - luspatercept

إسرائيل - العبرية - Ministry of Health

bristol, myers squibb (israel) limited, israel - luspatercept - אבקה להכנת תמיסה לזריקה - luspatercept 75 mg - luspatercept

إسرائيل - العبرية - Ministry of Health

bristol, myers squibb (israel) limited, israel - azacitidine - טבליות מצופות פילם - azacitidine 200 mg - azacitidine

إسرائيل - العبرية - Ministry of Health

bristol, myers squibb (israel) limited, israel - azacitidine - טבליות מצופות פילם - azacitidine 300 mg - azacitidine

إسرائيل - العبرية - Ministry of Health

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 250 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

إسرائيل - العبرية - Ministry of Health

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 500 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

إسرائيل - العبرية - Ministry of Health

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 1000 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

إسرائيل - العبرية - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob